Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

about

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Item

http://www.wikidata.org/entity/Q38567540

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

@en

type

Item

label

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

@en

prefLabel

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

@en

P1476

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

@en

P2093

Giovanni Barosi

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

P2888

s11899-015-0281-2

P304

362-369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-015-0281-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052964243

http://www.w3.org/2001/XMLSchema#string

P698

26277615

http://www.w3.org/2001/XMLSchema#string